Globe Life Inc.

Fundamentals8.0
Price Action6.0
News Sentiment6.0
AI Rating
7.0

Key Drivers

  • High margins
  • Strong FCF
  • Low cash balances

AI
AI Summary

7.0

GL's story has shifted from a yield/interest-rate play to a capital-return and distribution-growth thesis that is materially contingent on Bermuda reinsurance execution and the persistence of recent one‑time mortality/remeasurement benefits—if those don't materialize, near-term EPS and buyback/dividend capacity could compress quickly. Action: watch Bermuda approval/timing and parent liquidity (cash ~ $145M) as primary execution triggers and flag a reassessment if Bermuda delays exceed a quarter, parent cash stays < $200M, or remeasurement benefits drop below ~$50M.

CapitalReturn
BermudaRisk
Valuation‍

Price Chart

Loading chart...

Financial Metrics

-
Revenue (TTM)
-
Net Income (TTM)
-
EPS (Q)
-
MCAP

Deep Analysis

Research tool. Not personalized advice.

Fundamental Analysis

8.0

Key Financial Insights:

  • High margins
  • Strong FCF
  • Low cash balances

GL exhibits robust profitability and strong free cash flow with conservative valuation and low payout, but limited on‑hand cash, large off‑cash investments and some accounting items warrant closer scrutiny.

StrongMargins
LiquidityRisk

Price Behavior

6.0
Research tool. Not personalized advice. Technical analysis is for informational purposes only.

Key Price Behavior Insights:

  • Short-term downtrend
  • Mid-$146 resistance
  • Support near $136.50

GL is in a short-term downtrend over the last month—down ~5.9% from $142.29 to $136.80—facing mid-$146 resistance while holding nearby support around $136.50, so momentum favors sellers but a clear stop can define risk-reward.

Bearish
Watchlist
Support Level: $136.50
Resistance Level: $146–$147

~5.9% decline over the last month from $142.29 to $136.80 with moderate multi-day volatility

Sentiment & News

6.0

Key News Insights:

  • Dividend increase
  • Insider sales
  • Cost/headwinds

Globe Life raised its dividend and drew "undervalued" analyst interest amid insider sales, institutional trimming, legal inquiries and industry cost pressures that cloud near‑term outlook.

DividendBoost
LegalRisk

The mix of a higher payout and apparent valuation appeal could support the stock, but insider selling, investor reductions and rising medical costs introduce execution and downside risk in the near term